The study was designed jointly by the manufacturer of the vaccine and academic investigators linked to Julius Clinical. It was a parallel group, randomised, placebo-controlled double-blind trial, involving 85,000 subjects aged 65 and older in the Netherlands.
Julius Clinical took the lead role in establishing and managing an extensive national network of more than 2,000 GPs in order to quickly achieve the recruitment goals. The primary clinical objective, and also both secondary clinical objectives, were achieved.
For CAPiTA, the principal investigator was Dr. Marc Bonten, who is a Professor of Molecular Epidemiology of Infectious Diseases.